Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B G Feagan

Showing results (61-70 of 75) with videos related to

Pageof 8
Sort By:
Alimentary Pharmacology & Therapeutics|September 25, 2015
Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn's diseaseB G Feagan, W J Sandborn, G D'Haens, et al.
Alimentary Pharmacology & Therapeutics|May 26, 2018
Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapyW J Sandborn, P Rutgeerts, C Gasink, et al.
Alimentary Pharmacology & Therapeutics|April 3, 2014
A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's diseaseB G Levesque, G R Greenberg, G Zou, et al.
Alimentary Pharmacology & Therapeutics|February 16, 2005
A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's diseaseB G Feagan, W J Sandborn, J P Baker, et al.
Gastroenterology|April 21, 2001
An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trialW J Sandborn, B G Feagan, S B Hanauer, et al.
Gut|April 11, 2006
Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trialG Van Assche, W J Sandborn, B G Feagan, et al.
Alimentary Pharmacology & Therapeutics|June 28, 2017
The development of a magnetic resonance imaging index for fistulising Crohn's diseaseM A Samaan, C A J Puylaert, B G Levesque, et al.
Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie|March 21, 2008
Review and clinical perspectives for the use of infliximab in ulcerative colitisR Panaccione, R N Fedorak, G Aumais, et al.
Alimentary Pharmacology & Therapeutics|June 2, 2017
Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitisG R D'Haens, W J Sandborn, G Zou, et al.
Gastroenterology|August 28, 1999
Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study GroupW J Sandborn, W J Tremaine, D C Wolf, et al.
Pageof 8

Showing results (61-70 of 75) with videos related to

Sort By:
Pageof 8
Alimentary Pharmacology & Therapeutics|September 25, 2015
Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn's diseaseB G Feagan, W J Sandborn, G D'Haens, et al.
Alimentary Pharmacology & Therapeutics|May 26, 2018
Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapyW J Sandborn, P Rutgeerts, C Gasink, et al.
Alimentary Pharmacology & Therapeutics|April 3, 2014
A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's diseaseB G Levesque, G R Greenberg, G Zou, et al.
Alimentary Pharmacology & Therapeutics|February 16, 2005
A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's diseaseB G Feagan, W J Sandborn, J P Baker, et al.
Gastroenterology|April 21, 2001
An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trialW J Sandborn, B G Feagan, S B Hanauer, et al.
Gut|April 11, 2006
Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trialG Van Assche, W J Sandborn, B G Feagan, et al.
Alimentary Pharmacology & Therapeutics|June 28, 2017
The development of a magnetic resonance imaging index for fistulising Crohn's diseaseM A Samaan, C A J Puylaert, B G Levesque, et al.
Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie|March 21, 2008
Review and clinical perspectives for the use of infliximab in ulcerative colitisR Panaccione, R N Fedorak, G Aumais, et al.
Alimentary Pharmacology & Therapeutics|June 2, 2017
Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitisG R D'Haens, W J Sandborn, G Zou, et al.
Gastroenterology|August 28, 1999
Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study GroupW J Sandborn, W J Tremaine, D C Wolf, et al.
Pageof 8